FERMT2 and neoplasm: Recent research has demonstrated that FERMT2 is overexpressed in many tumor types, including gastric [5], breast [8, 9], kidney [44], glioblastoma [45], pancreatic [6, 7], bladder [46], prostate [47], hepatocellular [48] and esophageal [49] cancer, and associated with tumor progression and poor prognosis.